Morphotek Inc. Expands Its Phase II Trial Site Selections in the European Union
8/26/2008 8:06:43 AM
EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, today announced that it has opened clinical sites in the European Union (EU) as part of the company’s MORAb-009 Phase II study. The study is evaluating MORAb-009, a monoclonal antibody to mesothelin, as a first-line treatment for patients with pancreatic cancer. The randomized, controlled, double-blinded trial will compare MORAb-009 plus gemcitabine with a placebo plus gemcitabine.
comments powered by